CADL

Candel Therapeutics, Inc. (CADL) | Rumor.io

Candel Therapeutics

CADL

Attention (50-day avg)0.03%

Attention rank (50-day avg)#239

Bullish sentiment (50-day avg)85%

Price to earnings ratio-15.6

Market capitalization856.2M

Earnings per share-1.47

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-38.2M

Social

What share of all stock conversation is about CADL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% +0.02	0.01% -0.01	0.02% -0.01	0.01% -0.01

Sep 29

$CADL has a market cap of $800 million and $200 million in cash, with a potential catalyst 3 months away.
The company's Phase 3 extended data for Aglatimagene besadenovec (CAN-2409) will be presented at ASTRO on September 29, 2026, with BLA submission expected.
Institutions own 75.8% of CADL, and the stock price has been volatile, with some analysts expecting a potential buy opportunity in the low 10s.

Generated by AI

Sentiment

Of the messages about CADL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	69.79% -27.18	84.98% -7.32	81.33% -5.54	88.09% +3.57
Bearish	30.21% +27.18	15.02% +7.32	18.67% +5.54	11.91% -3.57

Bullish· Sep 21

Candel Therapeutics, Inc. ($CADL) has a peak sales potential of $1.5B, significantly higher than the assumed $1.5B, suggesting a much higher valuation of $3B to $7.5B.
Analyst Alec's price target of $18 is considered too low, with some predicting a minimum price of $25, indicating a strong bullish sentiment.
Despite initial hesitation, Bank of America's upgrade to Buy and raised price target to $18 has sparked a positive trend, with the stock retracing 13.8% and closing above $10 for the 36th day in a row, and above $9 for the 64th day in a row.

Bearish· Sep 11

The asset's price has been subject to significant volatility, with a notable decline of -12% on 1.5 million shares after 90 minutes.
The company's management has been accused of self-inflicted damage, with some users suggesting that the CEO's selling of shares contributed to the decline.
Market makers are suspected of manipulating the share price to protect their futures contracts and achieve their OpEx Max Pain Point Close, which could lead to further price drops.

Generated by AI

Topics

Of the messages about CADL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	29.17%	48.28%	52.82%	57.25%
Technical Analysis	37.5%	27.59%	29.08%	31.99%
Analysts	0%	1.72%	11.57%	7.16%
Macro	33.33%	22.41%	3.86%	2.4%
Controversies	0%	0%	2.67%	0.84%
Earnings	0%	0%	0%	0.36%

Announcements· Jun 30

Candel Therapeutics, Inc. ($CADL) has initiated a global pivotal Phase 3 AURORA trial evaluating aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer patients with inadequate response to immune checkpoint inhibitors.
The Phase 3 trial will enroll patients with metastatic non-squamous non-small cell lung cancer and will be conducted in collaboration with leading clinical trial sites, including NYU Langone Health, the University of Pennsylvania, and Yale Cancer Center.
Analysts estimate the peak revenue potential for CAN-2409 across its target indications to be approximately $2.9 billion, with the localized prostate cancer indication being Candel's near-term value driver, with a planned Biologics License Application (BLA) submission to the FDA in Q4 2026.

Technical Analysis· Feb 20

$CADL is expected to hit $4.50, with some traders adding more shares if it reaches that price.
A double bottom pattern has been established at $5.45, suggesting a potential bottom and possible price increase to $3.90 by late spring.
The stock is currently trading in a tight range near support, with a coil forming that could resolve quickly if buyers step in, presenting an asymmetry setup.

Generated by AI

Community

Of the messages about CADL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.18%	98%	96.56%	88.02%
Newcomers	2.82%	2%	3.44%	11.98%

Regulars· Sep 29

The market is anticipating news from Candel Therapeutics, Inc. (CADL) tomorrow, which could be related to the fireside chat and Biotech TV.
The regulars are focused on the BLA (Biologics License Application) and its potential impact on CADL's stock price, with one user comparing it to IOVA's successful BLA process.
The current price of CADL is attractive for buying, with some users expecting a potential bounce or reversal in the stock price, while others are concerned about the timing and the company's progress.

Newcomers· Aug 31

Newcomers to the CADL asset are excited about the upcoming catalysts in September, particularly the extended Phase 3 prostate cancer data and the planned FDA BLA filing for CAN-2409.
The asset's core logic is viewed as a simple equation: Phase 3 success, followed by ASTRO extended data, Q4 2026 BLA submission, FDA review, and potential commercialization.
The CAN-2409 NSCLC Phase 3 + CAN-3110 brain cancer program provides additional long-term value for the asset, in addition to the upcoming catalysts, making it an attractive opportunity for some investors.

Generated by AI

News

Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 (CADL)

7d agoSeeking Alpha

H.C. Wainwright Remains a Buy on Candel Therapeutics (CADL)

Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.

7d agotheglobeandmail.com

Why is Candel Therapeutics stock surging today?

8d agoInvesting.com

Candel Therapeutics Shares Rise After BofA Upgrade

Candel Therapeutics (CADL) shares rose 3.9% in Monday trading after BofA upgraded the stock to buy f

8d agoYahoo Finance

BofA upgrades Candel Therapeutics stock rating on prostate cancer progress

8d agoInvesting.com

Candel Therapeutics stock jumps on BofA upgrade to buy

8d agoInvesting.com

Also Discussed

Investors talking about CADL also mention

#	Name	Attention
1	Capricor Therapeutics, Inc.CAPR	0.35%+0.26
2	Replimune Group, Inc.REPL	0%0
3	ImmunityBio Inc.IBRX	0.28%-0.07
4	KYCH - Keyarch Acquisition Corporation	——
5	C4 Therapeutics IncCCCC	0%new
6	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91
7	Maia Biotechnology Inc.MAIA	0%0
8	Alvotech SAALVO	0%new
9	VRNA - Verona Pharma plc	——
10	Rallybio Corp.RLYB	0%0

Candel Therapeutics, Inc.

Healthcare
Biotechnology

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer. Candel Therapeutics concentrates on off-the-shelf, multimodal biological therapies designed to stimulate anti-tumor immune responses and address solid tumors. Its current pipeline includes CAN-2409, an adenovirus-based program being evaluated in cancers such as prostate, non-small cell lung, and pancreatic cancer, as well as CAN-3110, a herpes simplex virus-based candidate for recurrent high-grade glioma. The company also develops the enLIGHTEN Discovery Platform, which is used to identify and advance new viral immunotherapy candidates. Headquartered in Needham, Massachusetts, Candel Therapeutics plays a specialized role in oncology by combining viral engineering with immunology to support the development of targeted cancer treatments.

Website

Location

117 Kendrick Street

Needham, MA, 02494

United States

Social

What share of all stock conversation is about CADL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% +0.02	0.01% -0.01	0.02% -0.01	0.01% -0.01

Sep 29

$CADL has a market cap of $800 million and $200 million in cash, with a potential catalyst 3 months away.
The company's Phase 3 extended data for Aglatimagene besadenovec (CAN-2409) will be presented at ASTRO on September 29, 2026, with BLA submission expected.
Institutions own 75.8% of CADL, and the stock price has been volatile, with some analysts expecting a potential buy opportunity in the low 10s.

Generated by AI

Sentiment

Of the messages about CADL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	69.79% -27.18	84.98% -7.32	81.33% -5.54	88.09% +3.57
Bearish	30.21% +27.18	15.02% +7.32	18.67% +5.54	11.91% -3.57

Bullish· Sep 21

Candel Therapeutics, Inc. ($CADL) has a peak sales potential of $1.5B, significantly higher than the assumed $1.5B, suggesting a much higher valuation of $3B to $7.5B.
Analyst Alec's price target of $18 is considered too low, with some predicting a minimum price of $25, indicating a strong bullish sentiment.
Despite initial hesitation, Bank of America's upgrade to Buy and raised price target to $18 has sparked a positive trend, with the stock retracing 13.8% and closing above $10 for the 36th day in a row, and above $9 for the 64th day in a row.

Bearish· Sep 11

The asset's price has been subject to significant volatility, with a notable decline of -12% on 1.5 million shares after 90 minutes.
The company's management has been accused of self-inflicted damage, with some users suggesting that the CEO's selling of shares contributed to the decline.
Market makers are suspected of manipulating the share price to protect their futures contracts and achieve their OpEx Max Pain Point Close, which could lead to further price drops.

Generated by AI

Topics

Of the messages about CADL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	29.17%	48.28%	52.82%	57.25%
Technical Analysis	37.5%	27.59%	29.08%	31.99%
Analysts	0%	1.72%	11.57%	7.16%
Macro	33.33%	22.41%	3.86%	2.4%
Controversies	0%	0%	2.67%	0.84%
Earnings	0%	0%	0%	0.36%

Announcements· Jun 30

Candel Therapeutics, Inc. ($CADL) has initiated a global pivotal Phase 3 AURORA trial evaluating aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer patients with inadequate response to immune checkpoint inhibitors.
The Phase 3 trial will enroll patients with metastatic non-squamous non-small cell lung cancer and will be conducted in collaboration with leading clinical trial sites, including NYU Langone Health, the University of Pennsylvania, and Yale Cancer Center.
Analysts estimate the peak revenue potential for CAN-2409 across its target indications to be approximately $2.9 billion, with the localized prostate cancer indication being Candel's near-term value driver, with a planned Biologics License Application (BLA) submission to the FDA in Q4 2026.

Technical Analysis· Feb 20

$CADL is expected to hit $4.50, with some traders adding more shares if it reaches that price.
A double bottom pattern has been established at $5.45, suggesting a potential bottom and possible price increase to $3.90 by late spring.
The stock is currently trading in a tight range near support, with a coil forming that could resolve quickly if buyers step in, presenting an asymmetry setup.

Generated by AI

Community

Of the messages about CADL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.18%	98%	96.56%	88.02%
Newcomers	2.82%	2%	3.44%	11.98%

Regulars· Sep 29

The market is anticipating news from Candel Therapeutics, Inc. (CADL) tomorrow, which could be related to the fireside chat and Biotech TV.
The regulars are focused on the BLA (Biologics License Application) and its potential impact on CADL's stock price, with one user comparing it to IOVA's successful BLA process.
The current price of CADL is attractive for buying, with some users expecting a potential bounce or reversal in the stock price, while others are concerned about the timing and the company's progress.

Newcomers· Aug 31

Newcomers to the CADL asset are excited about the upcoming catalysts in September, particularly the extended Phase 3 prostate cancer data and the planned FDA BLA filing for CAN-2409.
The asset's core logic is viewed as a simple equation: Phase 3 success, followed by ASTRO extended data, Q4 2026 BLA submission, FDA review, and potential commercialization.
The CAN-2409 NSCLC Phase 3 + CAN-3110 brain cancer program provides additional long-term value for the asset, in addition to the upcoming catalysts, making it an attractive opportunity for some investors.

Generated by AI

Candel Therapeutics

Social

Sep 29

Bullish· Sep 21

Bearish· Sep 11

Announcements· Jun 30

Technical Analysis· Feb 20

Regulars· Sep 29

Newcomers· Aug 31

Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 (CADL)

H.C. Wainwright Remains a Buy on Candel Therapeutics (CADL)

Why is Candel Therapeutics stock surging today?

Candel Therapeutics Shares Rise After BofA Upgrade

BofA upgrades Candel Therapeutics stock rating on prostate cancer progress

Candel Therapeutics stock jumps on BofA upgrade to buy

Also Discussed

Candel Therapeutics, Inc.

Company Information

Location

Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 (CADL)

H.C. Wainwright Remains a Buy on Candel Therapeutics (CADL)

Why is Candel Therapeutics stock surging today?

Candel Therapeutics Shares Rise After BofA Upgrade

BofA upgrades Candel Therapeutics stock rating on prostate cancer progress

Candel Therapeutics stock jumps on BofA upgrade to buy

Also Discussed

Social

Sep 29

Bullish· Sep 21

Bearish· Sep 11

Announcements· Jun 30

Technical Analysis· Feb 20

Regulars· Sep 29

Newcomers· Aug 31